Atossa Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
9.98M
on 2026-06-30, from 8.37M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-15 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
S-3 of 2024-05-13. Not read yet. S-3 ↗
$50.0M
Rodman & Renshaw, agreement of 2026-02-20. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Cash
2.9 quarters
$26.1M on 2026-06-30 ÷ $8.9M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-06-10 | Registered direct offering | 1,363,637 | $3.30 | $4.5M | 424B5 ↗ |